Effectiveness and safety of narlaprevir in real clinical practice of chronic hepatitis
Objective: to analyze the efficacy and safety of using direct antiviral action drug narlaprevir/ritonavir in combination with the prolonged alpha-interferon and ribavirin drugs in the conditions of day-time hospitals of St. Petersburg and Novgorod. Materials and methods: The study included 35 patients with CHC of the 1st genotype. For treating these patients, a three-component regimen was used, which included the use of narlaprevir/ritonavir in combination with peg-interferon and ribavirin. Results: among all patients included in the study, a sustained virological response was noted in 85,7%. Early virological response was observed in 91,3% cases. The recurrence rate was observed in 10% patients. In 3 patients, therapy was interrupted for the following reasons: due to inefficiency, the development of serious adverse events, and on its own initiative. Conclusion: the data obtained demonstrate high virological and clinical efficacy and safety of narlaprevir in combination with peg-interferon and ribavirin, in the treatment of chronic viral hepatitis C.